Camlin Fine Q2 FY27 Earnings Call — Analysis (NSE: CAMLINFINE)
Camlin Fine Sciences plans a ₹250 Cr rights issue to ease severe liquidity stress and targets a Q4FY27 turnaround with ₹600 Cr revenue and 10% EBITDA.
Result quality: poor — Loss widened. Management sentiment: optimistic.
The take
Q2FY27 Aroma Revenue ₹47.2 Cr ( -₹30.2 Cr QoQ ) . Guidance raised — Q4FY27 q4 fy27 vanillin sales volume 1,000 metric tons per quarter . But walked back — Working capital and financing strain . New story: Blends growth engine .
Results
Gross margins contracted by ~200 bps to ₹195.8 Cr and reported EBITDA margin dropped to 2.5% due to input cost pressure, freight inflation, and high financing costs on payables.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Gross Profit | ₹195.8 Cr | -₹18.4 Cr | sequential · Q2FY27 · vs ₹214.2 Cr in Q1FY27 |
| EBITDA Margin | 2.5% | -90bps | sequential · Q2FY27 · vs 3.4% in Q1FY27 |
| Aroma Revenue | ₹47.2 Cr | -₹30.2 Cr | sequential · Q2FY27 · vs ₹77.4 Cr in Q1FY27 |
| Specialty Ingredients Revenue | ₹408.9 Cr | +₹7.6 Cr | sequential · Q2FY27 · vs ₹401.3 Cr in Q1FY27 |
| Net Debt | ₹538.0 Cr | +₹12.0 Cr | sequential · Q2FY27 · vs ₹526.0 Cr in Q1FY27 |
Guidance
Management expects Q4FY27 revenue to cross ₹600 Cr with ~10% EBITDA margin (~₹60 Cr+) following the receipt of ₹250 Cr rights issue proceeds.
What management committed to
- [Camlin Fine Sciences] expects Q4 FY27 consolidated turnover of INR6,000 million (₹600 crore) and EBITDA of INR60 crore plus, implying a return to double-digit EBITDA margin. — INR6,000 million turnover; INR60+ crore EBITDA, Q4FY27
- [Camlin Fine Sciences] will complete the rights issue of INR250 crores and have the funds available by end of calendar year 2026 or early January 2027. — INR250 crores, Q4FY27
- [Camlin Fine Sciences] expects vanillin sales volume of 1,000 metric tons per quarter starting from Q4 FY27, driven by U.S. and European demand. — 1,000 metric tons per quarter, Q4FY27
- [Camlin Fine Sciences] expects to add at least INR500 million in incremental blends revenue in Q4 FY27 as liquidity constraints ease. — INR500+ million, Q4FY27
- [Camlin Fine Sciences] expects Q3 FY27 consolidated EBITDA margin to be tad better than Q2 FY27, staying below double digits. — marginally higher than 2.5%, Q3FY27
- [Camlin Fine Sciences] targets reducing diphenol plant maintenance cash burn to INR25 million per quarter by Q4 FY27. — INR25 million per quarter, Q4FY27
Key themes
Liquidity crunch, rights issue, and vanillin turnaround
How the narrative shifted
- Raw material and freight squeeze: The narrative now integrates Chinese competition as an aggravation mechanism preventing pass-through of raw material costs.
- Vanillin capacity utilization ramp: Shifted from 'undoubtable Q3 double-digit ramp' to 'green shoots in Q4 after rights issue'.
- Blends growth engine: Emphasis shifted from 'Q2 improvement assumed' to 'held back by lack of liquidity, not lack of demand'.
- Working capital and financing strain: Escalated from 'bit of a concern' to 'main culprit' requiring immediate equity infusion.
- Segment disclosure and restructuring: The three-segment disclosure structure was used but not highlighted as a strategic milestone as in the prior call.
- Diphenol shutdown and strategic alternatives:
Operational commentary
- Board approved a rights issue of ~₹250 Cr to stabilize working capital and unwind high-cost channel financing; promoter group commits to subscribe to their full 48% entitlement.
- Diphenol manufacturing plant remains mothballed since May 2026 due to unviable domestic phenol pricing vs cheaper Chinese hydroquinone imports; plant maintenance cash burn reduced to ₹5 Cr/quarter with target of ₹2.5 Cr/quarter by Q4FY27.
- Aroma vertical shifted focus toward ethyl vanillin with Q2 sales of 332-334 MT (total aroma 358 MT vs 580 MT sequentially); vanillin pricing circumvention via Thailand/Malaysia is being countered by Syensqo in the US and Europe.
- High channel financing costs and vendor financing penalties on overdue payables (~3-4% interest drag or ₹19-20 Cr per quarter) severely depressed reported gross margins.
Analyst Q&A
Q. Will Camlin meet its earlier FY27 guidance of ₹2,000 Cr top line and ₹200 Cr EBITDA (~10%)?
Management confirmed it will not reach the full-year target due to H1 weakness and delayed liquidity infusion, but expects Q4FY27 to hit ₹600 Cr top line and ₹60 Cr+ EBITDA.
Q. What is the status and future viability of the mothballed diphenol plant given massive capacity additions in China?
Chinese capacities and raw material prices are well below CFS's production costs; management stated there is no visibility on when or if the diphenol plant will ever restart.
Q. Why is Aroma reporting -23% EBITDA when unit EBITDA was guided at $2/ton?
The $2/kg EBITDA is based on 70% capacity utilization; at subscale volumes (358 MT), ₹20 Cr of unabsorbed quarterly fixed overhead resulted in an EBITDA loss of ₹11 Cr.
Research and educational content only. Not investment advice.